Syngene International Limited, a global contract research, development, and manufacturing organization (CRDMO), announced on Monday, January 19, an extension of its long-term strategic research collaboration with Bristol Myers Squibb, with the partnership now set to run until 2035. According to the company's filing, this expansion deepens a relationship that spans more than 25 years, with the collaboration originally beginning in 1998. The expanded agreement will broaden the scope of integrated services across the drug development lifecycle, including discovery and translational sciences along with pharmaceutical development, manufacturing, clinical trials, and data and IT services to enable seamless progression from research to commercialisation.
The collaboration is aimed at enabling seamless progression of drug candidates from early research to commercialisation. As reported by The Economic Times, Managing Director and CEO Peter Bains stated that the partnership is anchored in scientific excellence, operational reliability, and a shared commitment to advancing innovative therapies. Bains noted that the agreement to extend this partnership through 2035 enables both companies to plan together for the future in terms of building new capabilities and infrastructure with a decade-long horizon. The collaboration positions Syngene to support Bristol Myers Squibb's next wave of discovery, development and manufacturing programmes with the potential to improve patient outcomes globally.
The collaboration led to the establishment of the Biocon Bristol Myers Squibb Research and Development Center (BBRC), Syngene's first dedicated R&D centre, which was fully commissioned in 2009. According to the company, the BBRC has evolved into a major strategic R&D hub for Bristol Myers Squibb, supporting capabilities across target identification, lead discovery and optimisation, pharmaceutical development, molecular and cell biology, protein sciences, assay biology and clinical biomarkers. The centre currently houses around 700 Syngene scientists working as an extension of Bristol Myers Squibb's global research organisation, contributing to discovery, preclinical development and patent filings across therapeutic areas such as cardiovascular, fibrosis, immunology and oncology.
Bristol Myers Squibb Senior VP Therapeutic Discovery Sciences Payal Sheth highlighted the strategic importance of the expanded collaboration. As per The Economic Times, Sheth stated that "This expanded collaboration reflects our commitment to advancing innovative science by effective integration of our research, development, and manufacturing capabilities to accelerate the delivery of transformative medicines and bring hope to patients around the world who are waiting for new treatment options." The expansion marks the next phase of growth, reinforcing Syngene's position as a strategic partner delivering integrated, end-to-end scientific and manufacturing solutions.
As reported by brokerage firm Macquarie, the firm maintained its 'outperform' rating on Syngene with a price target of ₹835 apiece, indicating an upside potential of nearly 28% from its previous close. Macquarie believes that Syngene offers an attractive risk-reward profile and expects fundamentals to improve while valuations remain attractive. Shares of the company were trading marginally down at ₹627 as of 11:10 am, still higher than the intraday lows of ₹619.95. The stock has dropped 4.14% in the past one month.
